Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 2/20 | 0.35 |
| ▸ | LDHB | P07195 | 2/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5331221 | 0.99 | NAMPT (0.46) | NAMPTROCK2ROCK1KDM4EPOLB | |
| SCHEMBL14361792 | 0.88 | NAMPT (0.38) | NAMPTROCK2ROCK1KDM4EPOLB | |
| SCHEMBL14072168 | 0.87 | RPS6KA3 (0.48) | NAMPTROCK2ROCK1KDM4EPOLB | |
| SCHEMBL13952739 | 0.86 | NAMPT (0.49) | NAMPTROCK2ROCK1KDM4EPOLB | |
| SCHEMBL5332204 | 0.86 | NAMPT (0.49) | NAMPTROCK2ROCK1KDM4EPOLB | |
| SCHEMBL12256159 | 0.85 | NAMPT (0.48) | NAMPTROCK2ROCK1KDM4EPOLB | |
| SCHEMBL5455808 | 0.85 | NAMPT (0.48) | NAMPTROCK2ROCK1KDM4EPOLB | |
| SCHEMBL6431430 | 0.85 | NAMPT (0.48) | NAMPTROCK2ROCK1KDM4EPOLB | |
| SCHEMBL14388704 | 0.85 | NAMPT (0.48) | NAMPTROCK2ROCK1KDM4EPOLB | |
| SCHEMBL6433630 | 0.85 | NAMPT (0.45) | NAMPTROCK2ROCK1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017599-B2 | Sequence selective pyrrole and imidazole polyamide metallocomplexes | UNIVERSITY OF WESTERN SYDNEY (AU) | 2011-09-13 | — | — | US | disclosed |
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | UNIVERSITY OF WESTERN SYDNEY (AU) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | POLRMT, MPI, PPIF | NAMPT 495/4885ROCK2 3694/4885ROCK1 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.